Erste Asset Management’s Blueprint Medicines BPMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-25,100
| Closed | -$3.22M | – | 639 |
|
|
2025
Q2 | $3.22M | Hold |
25,100
| – | – | 0.03% | 334 |
|
|
2025
Q1 | $2.23M | Hold |
25,100
| – | – | 0.03% | 293 |
|
|
2024
Q4 | $2.24M | Hold |
25,100
| – | – | 0.03% | 312 |
|
|
2024
Q3 | $2.32M | Hold |
25,100
| – | – | 0.03% | 303 |
|
|
2024
Q2 | $2.72M | Hold |
25,100
| – | – | 0.04% | 278 |
|
|
2024
Q1 | $2.38M | Hold |
25,100
| – | – | 0.03% | 287 |
|
|
2023
Q4 | $2.29M | Hold |
25,100
| – | – | 0.03% | 283 |
|
|
2023
Q3 | $1.28M | Hold |
25,100
| – | – | 0.02% | 317 |
|
|
2023
Q2 | $1.67M | Hold |
25,100
| – | – | 0.03% | 298 |
|
|
2023
Q1 | $1.11M | Hold |
25,100
| – | – | 0.02% | 351 |
|
|
2022
Q4 | $1.08M | Hold |
25,100
| – | – | 0.02% | 349 |
|
|
2022
Q3 | $1.65M | Hold |
25,100
| – | – | 0.04% | 303 |
|
|
2022
Q2 | $1.31M | Hold |
25,100
| – | – | 0.03% | 324 |
|
|
2022
Q1 | $1.63M | Sell |
25,100
-2,500
| -9% | -$179K | 0.03% | 314 |
|
|
2021
Q4 | $3.02M | Hold |
27,600
| – | – | 0.05% | 259 |
|
|
2021
Q3 | $2.86M | Hold |
27,600
| – | – | 0.06% | 251 |
|
|
2021
Q2 | $2.42M | Hold |
27,600
| – | – | 0.05% | 267 |
|
|
2021
Q1 | $2.57M | Hold |
27,600
| – | – | 0.06% | 242 |
|
|
2020
Q4 | $3.22M | Sell |
27,600
-25,100
| -48% | -$2.65M | 0.09% | 207 |
|
|
2020
Q3 | $4.83M | Buy |
52,700
+5,100
| +11% | +$393K | 0.16% | 147 |
|
|
2020
Q2 | $3.64M | Hold |
47,600
| – | – | 0.15% | 157 |
|
|
2020
Q1 | $2.76M | Hold |
47,600
| – | – | 0.16% | 156 |
|
|
2019
Q4 | $3.87M | Hold |
47,600
| – | – | 0.17% | 134 |
|
|
2019
Q3 | $3.48M | Hold |
47,600
| – | – | 0.19% | 129 |
|
|
2019
Q2 | $4.41M | Buy |
47,600
+13,200
| +38% | +$1.09M | 0.23% | 112 |
|
|
2019
Q1 | $2.6M | Hold |
34,400
| – | – | 0.15% | 145 |
|
|
2018
Q4 | $1.74M | Buy |
+34,400
| New | +$2.09M | 0.12% | 171 |
|
Other funds holding BPMC
IA
HNB
Erste Asset Management's BPMC Position: Q3 2025 in Review
Erste Asset Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 25,100 shares — an estimated $3.22M sold.
Erste Asset Management first reported a position in BPMC in Q4 2018 and held it in 27 quarters. The position peaked at $4.83M in Q3 2020. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.
- Erste Asset Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
- Erste Asset Management sold 25,100 Blueprint Medicines shares in Q3 2025, an estimated $3.22M.
- Erste Asset Management first reported a position in Blueprint Medicines in Q4 2018 and held it in 27 quarters.
- Erste Asset Management's Blueprint Medicines position peaked at $4.83M in Q3 2020.
- 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.
Based on Erste Asset Management's 13F filing for Q3 2025, filed 12 Nov 2025.